The Renin Angiotensin System: From Physiology to Novel Therapeutics

A Special Issue of Biomedicines (ISSN 2227-9059) belonging to the section "Molecular and Translational Medicine".

Deadline for manuscript submissions: 30 April 2027 | Viewed by 820

Editors


E-Mail Website
Guest Editor
Department of Physical Therapy, Lebanon Valley College, Annville, PA, USA
Interests: autonomic nervous system; blood flow regulation; blood pressure control; postural orthostatic tachycardia syndrome

E-Mail Website
Guest Editor
Department of Medicine, Nephrology, University of Rochester Medical Center, Rochester, NY, USA
Interests: neural control; renin angiotensin system; blood flow regulation; metabolic function
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The renin–angiotensin system remains a cornerstone of cardiovascular, renal and metabolic physiology, with far-reaching implications for human health and disease. Beyond its classical role in blood pressure regulation and fluid–electrolyte homeostasis, contemporary research has revealed an increasingly complex and tissue-specific network influencing inflammation, fibrosis, immune modulation, neurohumoral signaling and cellular metabolism. These advances have expanded the relevance of the renin–angiotensin system to a broad spectrum of conditions, including hypertension, heart failure, chronic kidney disease, metabolic disorders, neurodegenerative diseases and emerging infectious and inflammatory pathologies.

This Special Issue aims to provide a comprehensive and forward-looking overview of the current state of renin–angiotensin system research, integrating fundamental mechanisms with translational and clinical perspectives. We invite original research articles, state-of-the-art reviews and concise perspectives that address established and novel components of the renin–angiotensin system, including but not limited to angiotensin peptides, receptors, enzymes, intracellular and tissue-specific renin–angiotensin system signaling and interactions with other regulatory systems.

Topics of interest include advances in renin–angiotensin system pharmacology and therapeutics, emerging drug targets, precision and sex-specific medicine, genetic and epigenetic regulation and the role of the renin–angiotensin system in aging and chronic disease progression. Contributions exploring innovative methodologies, biomarkers and future clinical applications are particularly encouraged.

By bringing together diverse perspectives from basic science to clinical investigation, this Special Issue seeks to highlight critical knowledge gaps, stimulate interdisciplinary dialogue and define future directions for research and therapeutic innovation within the evolving landscape of the renin–angiotensin system.

Dr. Amanda J. Miller 
Prof. Dr. Yumei Feng Earley
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • renin-angiotensin system
  • physiology
  • neural control
  • translational therapeutics

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

17 pages, 1533 KB  
Article
The Potential of Alamandine in Airway Hyperresponsiveness in an Ovalbumin-Induced Asthma Model
by Vitória Nedel Rech, Andresa Thomé Silveira, Giuliano Rizzotto Guimarães and Katya Rigatto
Biomedicines 2026, 14(8), 1832; https://doi.org/10.3390/biomedicines14081832 - 14 Aug 2026
Viewed by 453
Abstract
Background: Asthma is a chronic inflammatory airway disease characterized by variable airflow obstruction and tissue remodeling. Alamandine (ALA), a renin–angiotensin system (RAS) peptide with anti-inflammatory properties, remains poorly explored in allergic respiratory disease. Objectives: This study evaluated prophylactic (33 days) and therapeutic [...] Read more.
Background: Asthma is a chronic inflammatory airway disease characterized by variable airflow obstruction and tissue remodeling. Alamandine (ALA), a renin–angiotensin system (RAS) peptide with anti-inflammatory properties, remains poorly explored in allergic respiratory disease. Objectives: This study evaluated prophylactic (33 days) and therapeutic (21 days) subcutaneous ALA (50 µg/kg/day) administration in an ovalbumin (OVA)-induced rat asthma model. Methods: Twenty male Wistar rats were assigned to four groups: control (CO), OVA with prophylactic ALA (ALA-P; days 1–33), OVA with therapeutic ALA (ALA-T; days 12–33), and OVA-only control (OVA). Rats were sensitized (days 1–3) and challenged with aerosolized OVA (days 6–33). On day 34, ventilatory mechanics were assessed via FlexiVent, including methacholine challenge (12.5 mg/mL). Pulmonary inflammation was evaluated by eosinophil quantification; MrgD/Mas and AT1 receptor expression by immunohistochemistry and Western blot, respectively. Results: OVA animals exhibited elevated baseline airway resistance and bronchoconstriction, and eosinophil infiltration. ALA-T significantly attenuated the respiratory symptoms, restoring airway resistance and eosinophil infiltration to CO-group levels, whereas ALA-P exhibited only a partial reduction. MrgD and Mas expression were elevated in OVA, reflecting compensatory RAS activation, but normalized in both ALA-treated groups. No significant differences in AT1 expression were observed. Conclusions: ALA likely exerts bronchoprotective and anti-allergic effects in this model via MrgD/Mas modulation. The ALA–MrgD/Mas axis represents a potential therapeutic target for allergic airway diseases, particularly when conventional treatments are insufficient. Full article
(This article belongs to the Special Issue The Renin Angiotensin System: From Physiology to Novel Therapeutics)
Show Figures

Figure 1

Back to TopTop